InvestorsHub Logo
Followers 29
Posts 2503
Boards Moderated 0
Alias Born 04/09/2010

Re: None

Wednesday, 01/08/2014 8:27:34 AM

Wednesday, January 08, 2014 8:27:34 AM

Post# of 97239
$CPRX

8:03 am Catalyst Pharma reports 'Positive' cardiac safety results of its Phase 3 product, Firdapse tablets; the study met the pre-specified primary endpoint (CPRX) : Co announced positive results from a study jointly funded with, and conducted by BioMarin Pharma (BMRN) to assess the cardiac safety of Firdapse tablets (amifampridine also known as 3,4-DAP). Firdapse is approved in the E.U., where it is marketed by BioMarin. Firdapse is also currently in Phase 3 development in the U.S. for Lambert-Eaton Myasthenic Syndrome (:LEMS) by Catalyst.
http://yhoo.it/1hvg7Ak

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.